Answers are grounded in this paper and cite their sources.
In March 2020, it was declared a state of pandemic coronavirus disease (COVID-19) by the World Health Organization, which represents a public health concern. Some vaccines were created to fight the COVID-19 disease and use nanotechnology in their composition. Vaccines approved in clinical trials that are currently available for the population using nanotechnology are BNT162b2 (Pfizer, 95% effective), and mRNA-1273 (Modern, 94, 5% effectiveness). These vaccines use lipid nanoparticles, loaded with RNA (mRNA) to fight SARS-Cov-2. Nanotechnology can have several advantages in creating vaccines, for example, antigen protection by premature degradation to increase the immune response, control release kinetics, provide site-specific antigens, and facilitate intracellular absorption. This review article seeks to present applications of nanostructures in the production of vaccines against COVID-19 that are in the clinical testing phase and also those that have already been approved.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: